SYMED LABS LTD

Overview

SYMED LABS LTD is an active pharmaceutical ingredient (API) supplier with 30 active FDA Type II Drug Master Files, covering BILASTINE (FORM-I); BILASTINE (FORM-II); BRIMONIDINE TARTRATE; CARBINOXAMINE MALEATE USP; DEFERASIROX; DRONEDARONE HYDROCHLORIDE.

API / Drug Master Files

SYMED LABS LTD holds 30 active (33 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• EZETIMIBE USPActive2026-01-10
• BILASTINE (FORM-I)Active2024-07-16
• OTILONIUM BROMIDEActive2024-06-28
• IRON SUCROSE (POWDER)Active2024-01-24
• EZETIMIBE USPActive2024-01-24
• HYDROXYCHLOROQUINE SULFATEActive2023-12-30
• VORTIOXETINE HYDROBROMIDE (FORM-ß)Active2023-12-30
• MODAFINIL USPActive2023-12-11
• BILASTINE (FORM-II)Active2023-10-09
• HYDROXYZINE PAMOATE USPActive2023-07-03
• SERTRALINE HYDROCHLORIDE (FORM-I) USPActive2023-03-16
• PRUCALOPRIDE SUCCINATEActive2020-09-25
• DEFERASIROXActive2019-11-20
• TIZANIDINE HYDROCHLORIDE USPActive2019-07-09
• SUCROFERRIC OXYHYDROXIDEActive2018-04-28

Showing 15 of 33 Drug Master Files.

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to SYMED LABS LTD in our records. PharmaTek screens the full directory against live FDA enforcement data.